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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Swiss French 
language. The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating 
centre was asked to collect demographic, clinical data, and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical 
validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, 
floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct 
validity (convergent and discriminant validity). A total of 98 JIA patients (3.1% systemic, 43.9% oligoarticular, 16.3% RF 
negative polyarthritis, 36.7% other categories), and 64 healthy children were enrolled in a paediatric rheumatology centre. 
The JAMAR components discriminated well healthy subjects from JIA patients. All JAMAR components revealed good 
psychometric performances. In conclusion, the Swiss French version of the JAMAR is a valid tool for the assessment of 
children with JIA and is suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Swiss French parent, child/adult version of 
the Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance, and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the epidemiol-
ogy, outcome, and treatment of childhood arthritis (EPOCA) 
in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Swiss French language. The Swiss German 
version of the JAMAR is currently under development.
Rheumatology
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The local members of the Paediatric Rheumatology International 
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6], and enrolled from June 2012 to 
January 2017. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR (1) includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has three com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scoring 
from 0 to 15 [7]. Higher scores indicate higher degree 
of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score 0), ‘sometimes’ (score 1), ‘most of the time’ 
(score 2) and ‘all the time’ (score 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted in 
a similar language (i.e., Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data, and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Lik-
ert assumption [mean and standard deviation (SD) equiva-
lence]; the second Likert assumption or equal item-scale 
correlations (Pearson r: all items within a scale should con-
tribute equally to the total score); third Likert assumption 
(item internal consistency or linearity for which each item 
of a scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intraclass correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core-set variables, with the addition 
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of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18]. Quantitative data were reported as medians 
with first and third quartiles and categorical data as absolute 
frequencies and percentages.
The complete Swiss French parent and patient versions of 
the JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Swiss French JAMAR was fully cross-culturally adapted 
from the standard English version with three forward and 
two backward translations with a concordance for 121/123 
(98.4%) translations lines for the parent version and 118/120 
(98.3%) lines for the child version.
All 123 lines of the parent version of the JAMAR were 
understood by at least 80% of the ten parents tested (median 
100%; range 80–100%). All the 120 lines of the patient ver-
sion of the JAMAR were understood by at least 80% of the 
children (median 100%; range 80–100%). The parent and 
child versions of the Swiss French JAMAR were unmodified 
after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 100 JIA patients and 67 healthy children (total of 
167 subjects) were enrolled at the paediatric rheumatology 
centre of Lausanne. Two patients and three healthy children 
did not give the consent to use their data.
In the remaining 98 JIA subjects, the JIA categories 
were 3.1% with systemic arthritis, 43.9% with oligoarthri-
tis, 16.3% with RF negative polyarthritis, 2% with psori-
atic arthritis, 25.5% with enthesitis-related arthritis, and 
9.2% with undifferentiated arthritis. Notably, none of the 
enrolled JIA patients is affected with RF positive polyar-
thritis (Table 1).
A total of 154/162 (95.1%) subjects had the parent ver-
sion of the JAMAR completed by a parent (96 from parents 
of JIA patients and 58 from parents of healthy children). The 
JAMAR was completed by 132/154 (85.7%) mothers and 
22/154 (14.3%) fathers. The child version of the JAMAR 
was completed by 102/162 (63%) children age 6.4 or older. 
In addition, patients younger than 7 years old, capable to 
assess their personal condition and able to read and write, 
were asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales, and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients. In summary, the JAMAR 
revealed that JIA patients had a greater level of disability 
and pain, as well as a lower HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a Web-based system that did not 
allow to skip answers and input of null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. All 
response choices were used for the different HRQoL items 
4, 6, and 8, whereas a reduced number of response choices 
were used for all the PF items.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items, 
except for HRQoL item 5 (data not shown). The median 
number of items marked as not applicable was 0% (0–1%) 
for the PF and 2% (1–3%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 87.5% (82.3–91.7%) for the 
PF items, 63.5% (51.0–66.7%) for the HRQoL PhH items, 
and 60.4% (59.4–61.5%) for the HRQoL PsH items. The 
median ceiling effect was 0% (0–0%) for the PF items, 5.2% 
(2.1–5.2%) for the HRQoL PhH items, and 2.1% (0–2.1%) 
for the HRQoL PsH items. The median floor effect was 
37.5% for the pain VAS, 35.4% for the disease activity VAS, 
and 35.4% for the well-being VAS. The median ceiling effect 
was 1.0% for the pain VAS, 2.1% for the disease activity 
VAS, and 1.0% for the well-being VAS.
Equal item‑scale correlations (second Likert 
assumption)
Pearson item-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 80% of the PF 
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Table 1  Descriptive statistics (medians, first–third quartiles or absolute frequencies, and %) for the 98 JIA patients
Data related to the JAMAR refer to the 96 JIA patients and to the 58 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic, N = 3 Oligoarthritis, 
N = 43
RF-polyarthri-
tis, N = 16
Psoriatic arthri-
tis, N = 2
Enthesitis-
related arthritis, 
N = 25
Undifferenti-
ated arthritis, 
N = 9
All JIA 
patients, N = 98
Healthy, N = 64
Female 3 (100%) 32 (74.4%) 14 (87.5%) 2 (100%) 14 (56%) 5 (55.6%) 70 (71.4%) 32 (50%)*
Age at visit 15.5 (11.5–
19.8)
9.5 (6.8–11.7) 15.8 (8.4–17.6) 15.1 (13.6–
16.5)
15.4 (11.7–
16.8)
11.1 (4.8–14.3) 11.6 (7.7–
16.3)*
8.4 (4.7–14.5)*
Age at onset 11 (8.1–14.2) 3.1 (1.8–6.6) 7.3 (2.2–10.9) 11.5 (11.4–
11.7)
10 (8.7–12.6) 5 (1.8-9) 6.8 (2.5–10.4)#
Disease duration 5.6 (0.6–7.3) 4.1 (2.3–8.3) 4.4 (2.9–9.8) 3.5 (1.9–5.2) 3.3 (2.2–5.4) 2.2 (1.7–6.1) 3.9 (2.2–7.3)
ESR 45 (11–70) 9.5 (7–16) 10 (7–17) 2 (2–2) 7.5 (5.5–15.5) 9.5 (6–22) 10 (6–17)
MD VAS 
(0–10 cm)
1 (0–5) 0 (0–1) 0.8 (0–4) 0.8 (0-1.5) 2 (1–3) 0 (0–1) 0.5 (0–2)*
No. swollen joints 0 (0–0) 0 (0–1) 0 (0–0) 5.5 (0–11) 0 (0–0) 0 (0–1) 0 (0–0)
No. joints with 
pain
0 (0–0) 0 (0–1) 0.5 (0-4.5) 1 (1–1) 3 (1–7) 0 (0–1) 0.5 (0–3)**
No. joints with 
LOM
0 (0–1) 0 (0–1) 0 (0-0.5) 2 (1–3) 0 (0–0) 0 (0–0) 0 (0–1)
No. active joints 0 (0–0) 0 (0–1) 0 (0-0.5) 6 (1–11) 0 (0–0) 0 (0–1) 0 (0–1)
Active systemic 
features
0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (8%) 0 (0%) 2 (2%)
ANA status 0 (0%) 5 (11.6%) 3 (18.8%) 0 (0%) 2 (8%) 2 (22.2%) 12 (12.2%)
Uveitis 0 (0%) 6 (14%) 1 (6.3%) 0 (0%) 1 (4%) 0 (0%) 8 (8.2%)
PF total score 0 (0–1) 0 (0–3) 1 (0–6) 0.5 (0–1) 3 (1–4) 1 (0–3) 1 (0–3) 0 (0–0)**
Pain VAS 2 (0.5–3.5) 0.5 (0–5) 1.5 (0-2.8) 0.5 (0–1) 3 (1.5-8) 0 (0-3.5) 1.8 (0-4.5) 0 (0–0)#
Disease activity 
VAS
0.5 (0-2.5) 1 (0-4.5) 2 (0-4.8) 0.5 (0–1) 3 (1-5.5) 0.5 (0-3.5) 1.8 (0-4.5)
Well-being VAS 0.5 (0–1) 0.5 (0–3) 2.8 (0.3–4.5) 0.3 (0-0.5) 2.5 (1.5–5.5) 0 (0–2) 1.3 (0–4)*
HRQoL PhH 4 (0–99) 1 (0–4) 3 (1–7) 1.5 (0–3) 2 (2–4) 1 (0–5) 2 (0–4) 0 (0–1)#
HRQoL PsH 99 (0–99) 1 (0–3) 2 (1–6) 0.5 (0–1) 1 (0–4) 1 (0–3) 1 (0–4) 0 (0–2)*
HRQoL total 
score
99 (0–99) 2 (0–8) 6.5 (2.5–12) 2 (1–3) 4 (2–9) 5 (0–10) 4 (1–9) 0 (0–4)**
Pain/swell. in > 1 
joint
2 (66.7%) 23 (53.5%) 10 (62.5%) 2 (100%) 22/23 (95.7%) 4 (44.4%) 63/96 (65.6%) 5/58 (8.6%)*
Morning stiff-
ness > 15 min
0 (0%) 8 (18.6%) 2 (12.5%) 0 (0%) 7/23 (30.4%) 0 (0%) 17/96 (17.7%) 2/58 (3.4%)*
Subjective remis-
sion
1 (33.3%) 23 (53.5%) 10 (62.5%) 1 (50%) 20/23 (87%) 2 (22.2%) 57/96 (59.4%)
In treatment 3 (100%) 17 (39.5%) 16 (100%) 0 (0%) 19/23 (82.6%) 6 (66.7%) 61/96 (63.5%)
Reporting side 
effects
0 (0%) 3/17 (17.6%) 5 (31.3%) 0 (0%) 5/19 (26.3%) 2/6 (33.3%) 15/61 (24.6%)
Taking medica-
tion regularly
3 (100%) 16/17 (94.1%) 15 (93.8%) 0 (0%) 19/19 (100%) 6/6 (100%) 59/61 (96.7%)
With problems 
attending 
school
0 (0%) 2/27 (7.4%) 3/12 (25%) 0 (0%) 4/15 (26.7%) 1/5 (20%) 10/61 (16.4%) 0 (0%)*
Satisfied with dis-
ease outcome
2 (66.7%) 29 (67.4%) 11 (68.8%) 2 (100%) 14/23 (60.9%) 8 (88.9%) 66/96 (68.8%)
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items, with the exception of items 5, 11, and 12, and for 90% 
of the HRQoL items, with the exception of item 1.
Items internal consistency (third Likert assumption)
Pearson item-scale correlations were ≥ 0.4 for 73% of items 
of the PF (except for PF items 5, 13, 14, and 15) and 100% 
of items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.75 for PF-LL, 0.83 for PF-HW, and 
0.68 for PF-US. Cronbach’s alpha was 0.85 for HRQoL PhH 
and 0.78 for HRQoL PsH.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent, N = 96/154 Child, N = 78/102
Missing values (first–third quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 87.5% 84.6%
 HRQoL PhH 63.5% 57.7%
 HRQoL PsH 60.4% 61.5%
 Pain VAS 37.5% 26.9%
 Disease activity VAS 35.4% 29.5%
 Well-being VAS 35.4% 33.3%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL PhH 5.2% 2.6%
 HRQoL PsH 2.1% 1.3%
 Pain VAS 1.0% 2.6%
 Disease activity VAS 2.1% 1.3%
 Well-being VAS 1.0% 1.3%
Items with equivalent item-scale correlation 80% for PF, 90% for HRQoL 87% for PF, 100% for HRQoL
Items with item-scale correlation ≥ 0.4 73% for PF, 100% for HRQoL 87% for PF, 90% for HRQoL
Cronbach’s alpha
 PF-LL 0.75 0.73
 PF-HW 0.83 0.79
 PF-US 0.68 0.75
 HRQoL PhH 0.85 0.86
 HRQoL PsH 0.78 0.76
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.79 0.78
 HRQoL PhH 0.87 0.84
 HRQoL PsH 0.00 0.29
Spearman correlation with JIA core-set variables, median
 PF 0.5 0.5
 HRQoL PhH 0.6 0.6
 HRQoL PsH 0.4 0.4
 Pain VAS 0.1 0.1
 Disease activity VAS 0.1 0.1
 Well-being VAS 0.1 0.1
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Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in nine JIA patients, by re-admin-
istering both versions (parent and child) of the JAMAR 
after a median of 15 days (range 12–16 days). The intra-
class correlation coefficients (ICC) for the PF total score 
showed a substantial reproducibility (ICC 0.79). The ICC 
for the HRQoL PhH showed an almost perfect reproduc-
ibility (ICC 0.87) and the ICC for the HRQoL PsH showed 
a poor reproducibility (ICC 0.0).
Convergent validity
The Spearman correlation of the PF total score with 
the JIA core set of outcome variables ranged from 0.1 
to 0.6 (median 0.5). The PF total score best correlation 
was observed with the parent assessment of well-being 
(r = 0.61, p < 0.001). For the HRQoL, the median corre-
lation of the PhH with the JIA core set of outcome vari-
ables ranged from 0.1 to 0.7 (median 0.6), whereas that 
for the PsH ranged from 0.1 to 0.6 (median 0.4). The PhH 
showed the best correlation with the parent’s assessment 
of pain (r = 0.74, p < 0.001) and the PsH with the parent’s 
assessment of pain (r = 0.71, p < 0.001). The median cor-
relations between the pain VAS, the well-being VAS, and 
the disease activity VAS and the physician-centred and 
laboratory measures were 0.1 (0.1–0.3), 0.1 (0.02–0.3), 
and 0.1 (0.1–0.3), respectively.
Discussion
In this study, the Swiss French version of the JAMAR was 
cross-culturally adapted from the standard English version 
with three forward and two backward translations. Accord-
ing to the results of the validation analysis, the Swiss French 
parent and patient versions of the JAMAR possess satis-
factory psychometric properties. The disease-specific com-
ponents of the questionnaire discriminated well between 
patients with JIA and healthy controls.
Psychometric performances were good for all domains 
of the JAMAR with a few exceptions: four PF items (“Bend 
down to pick up an object off the floor”, “Turn head and look 
over shoulders”, “Bend head back and look at the ceiling”, 
and “Bite into a sandwich or an apple”) showed a lower 
items internal consistency. However, the overall internal 
consistency was at least acceptable for all the domains 
(except for PF-US that is questionable).
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core-set 
parameters ranged from weak to strong.
The statistical performances of the child version of the 
JAMAR are very similar, although even better, to those 
obtained by the parent version, which suggests that chil-
dren are reliable reporters of their disease and health 
status.
The JAMAR is aimed to evaluate the side effects of 
medications and school attendance, which are other dimen-
sions of daily life that were not previously considered by 
other HRQoL tools. This may provide useful information 
for intervention and follow-up in health care. In conclu-
sion, the Swiss French version of the JAMAR was found to 
have satisfactory psychometric properties; and it is, thus, a 
reliable and valid tool for the multidimensional assessment 
of children with JIA.
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